Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company’s full-year revenue guidance of $9.22 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $1.87 per share was 1% above analysts’ consensus estimates.
Is now the time to buy Zoetis? Find out by accessing our full research report, it’s free.
Zoetis (ZTS) Q2 CY2026 Highlights:
- "Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories"
- Revenue: $2.47 billion vs analyst estimates of $2.50 billion (flat year on year, 1.5% miss)
- Adjusted EPS: $1.87 vs analyst estimates of $1.85 (1% beat)
- The company dropped its revenue guidance for the full year to $9.22 billion at the midpoint from $9.82 billion, a 6.1% decrease
- Management lowered its full-year Adjusted EPS guidance to $6.20 at the midpoint, a 10.5% decrease
- Market Capitalization: $31.19 billion
Company Overview
Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis (NYSE:ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide.
Revenue Growth
A company’s long-term sales performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Unfortunately, Zoetis’s 4.9% annualized revenue growth over the last five years was mediocre. This wasn’t a great result compared to the rest of the healthcare sector, but there are still things to like about Zoetis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Zoetis’s recent performance shows its demand has slowed as its annualized revenue growth of 2.7% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs. 
This quarter, Zoetis missed Wall Street’s estimates and reported a rather uninspiring 0.2% year-on-year revenue decline, generating $2.47 billion of revenue.
Looking ahead, sell-side analysts expect revenue to grow 5.2% over the next 12 months, an improvement versus the last two years. This projection is above the sector average and implies its newer products and services will catalyze better top-line performance.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Operating Margin
Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.
Zoetis has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average operating margin of 35.9%.
Looking at the trend in its profitability, Zoetis’s operating margin rose by 1.3 percentage points over the last five years, as its sales growth gave it operating leverage. The company’s two-year trajectory shows its performance was mostly driven by its recent improvements.
in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Zoetis’s EPS grew at 8.1% compounded annual growth rate over the last five years, higher than its 4.9% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
Diving into Zoetis’s quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Zoetis’s operating margin expanded by 1.3 percentage points over the last five years. On top of that, its share count shrank by 12.4%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. 
In Q2, Zoetis reported adjusted EPS of $1.87, up from $1.76 in the same quarter last year. This print was close to analysts’ estimates. Over the next 12 months, Wall Street expects Zoetis’s full-year EPS to grow 7.7% from $6.58 to $7.09.
Key Takeaways from Zoetis’s Q2 Results
We struggled to find many positives in these results. Its full-year revenue guidance missed and its full-year EPS guidance fell short of Wall Street’s estimates. Overall, this was a weaker quarter. Still, the stock traded up 4.6% to $77.81 immediately following the results.
Is Zoetis an attractive investment opportunity right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).